Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
Epidermolysis bullosa (EB) is an inherited connective tissue disease causing blisters in the skin and mucosal membranes, with an incidence of 1/50,000. It is a result of a defect in anchoring between the epidermis and dermis, resulting in friction and skin fragility. Its severity ranges from mild to lethal. Significance of EB: The human skin consists of two layers: an outermost layer called the epidermis and a layer underneath called the dermis. In individuals with healthy skin, there are protein anchors between these two layers that prevent them from moving independently from one another (shearing). In people born with EB, the two skin layers lack the protein anchors that hold them together, resulting in extremely fragile skin- even only minor mechanical friction (like rubbing or pressure) or trauma will separate the layers of the skin and form blisters and painful sores. Sufferers of EB have compared the sores with third-degree burns. Furthermore, as a complication of the chronic skin damage, people suffering from EB have an increased risk of malignancies (cancers) of the skin.
Importance and Scope:
Epidermolysis bullosa has significant medical and market potential. As many as 30,000 Americans suffer from the disease, a similar prevalence to cystic fibrosis, yet DEBRA the Dystrophic Epidermolysis Bullosa Research Association of America - often refers to EB as ‘the worst disease you’ve never heard of,’ he says. “EB is debilitating and potentially disfiguring. There are currently no FDA-approved treatments for EB, nor are there any effective treatments resulting from products approved for other indications.” The FDA has granted its breakthrough-therapy and orphan-drug designations to Zorblisa. The drug has also been granted orphan-drug status by the European Medicines Agency.
The Dermatologists industry is growing, due in large part to the aging population and the mounting awareness of the dangers of sun exposure. However, the industry is highly competitive. It is dominated by small establishments, and dermatologists are competing with lower-cost providers of similar services, such as medical spas. In response, dermatologists are progressively focusing on subspecialties, such as cosmetic dermatology or dermapathology. Dermatology market growth has averaged 6.7% a year in bn $.
OMICS Group Special Features: OMICS International Organizes 1000+ Global Events, 500+ workshops and 200+ symposiums on Clinical, Medicine, Pharma and Science & Technology every year across USA, Europe, Asia, Middle East, Australia and UK with support from 1000 more scientific societies and Publishes 700 open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.
OMICS Publishing Group manages over 700 peer reviewed Open Access Journals in all field of research and practical applications. OMICS group hosts 700 Open Access journals with over 3.5 million readers and therefore the honor and success of an equivalent are often attributed to the robust editorial board that contains over 30000 eminent personalities. These scientific events are emerging as one of the best gathering with the support from 1000 International Collaborations with renowned scientific societies and institutes. OMICS International events offer exciting chance to showcase the services of your company to the global audience.
OMICS Group follows an Open Access publication model that enables the dissemination of research articles to the global community free of cost. Abstracts and full texts (HTML, XML and PDF format) of all articles published by OMICS Group are freely accessible to everyone immediately after publication. All works published by OMICS Group are under the terms of Open Access Creative Commons Attribution License. This permits anyone to copy, distribute, transmit and adapt the work, provided if it is the original work and source is appropriately cited. We strongly believe that removing barriers to research published online will greatly aid to the progress in Clinical, Medical, Pharmaceutical, Chemistry, and Management disciplines.
OMICS Group supports the Bethesda Statement on Open Access Publishing. OMICS Scholarly Journals strictly adhere to standard review process. All the articles are subjected to peer-reviewing prior to publication. OMICS Group will keep up to date with latest advances in the respective fields and papers published in its journals will reach the readers directly through E-mail. Archived online transactions of OMICS Group provide the International scientific community with immediate and permanent access to individual papers. OMICS Group accepts online letters from the Editors and brief comments that contribute to the previously published articles or other relevant findings in OMICS field.
Musculoskeletal Regeneration Conference
May 05-06, 2016 Chicago, USA
6th Dermatology Conference
May 05-07, 2016 Chicago, USA
Euro Dermatology Conference
June 13-15, 2016 Alicantae, Spain
8th Clinical Dermatology Congress
September 07-09, 2016 Sao Paulo, Brazil
7th Pediatric Dermatology Conference
October 10-12, 2016 Manchester, UK
10th Dermatology Conference
November 10-12, 2016 Melbourne, Australia
11th Global Dermatologists Conference
November 14-16, 2016 Dubai, UAE
November 28-30, 2016 Baltimore, USA
August 01-03, 2016 Seattle, USA
Societies and Associations:
This page will be updated regularly.
This page was last updated on 11th Sep, 2015